Götze Katharina S, Lengerke Claudia
Medizinische Klinik und Poliklinik III, Hämatologie und Internistische Onkologie, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland.
Innere Medizin II - Hämatologie, Onkologie, klinische Immunologie und Rheumatologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
Inn Med (Heidelb). 2022 Nov;63(11):1107-1114. doi: 10.1007/s00108-022-01401-0. Epub 2022 Sep 20.
Clonal hematopoiesis of indeterminate potential (CHIP) is a fairly newly described phenomenon characterized by myeloid cancer-associated somatic mutations detectable in the peripheral blood of individuals without evidence of hematologic disease. Individuals with CHIP have a significantly increased risk of developing a hematologic malignancy, although the overall rate of transformation is low.
We review the current state of knowledge on causes of clonal expansion of blood cells as well as identifiable risk factors for progression to overt hematologic malignancy.
CHIP is considered a premalignant state and predisposes to the development of hematologic malignancy. Because the overall rate of transformation is low, clear identification and subsequent monitoring of those CHIP individuals at a higher risk is of paramount importance. In the future, prospective studies evaluating preventive and/or preemptive therapeutic strategies may aid in avoiding progression to blood cancer in individuals with CHIP.
意义未明的克隆性造血(CHIP)是一种相对较新描述的现象,其特征是在无血液系统疾病证据的个体外周血中可检测到与髓系癌相关的体细胞突变。患有CHIP的个体发生血液系统恶性肿瘤的风险显著增加,尽管总体转化发生率较低。
我们综述了关于血细胞克隆性扩增的原因以及进展为明显血液系统恶性肿瘤的可识别风险因素的当前知识状态。
CHIP被认为是一种癌前状态,易患血液系统恶性肿瘤。由于总体转化发生率较低,明确识别并随后监测那些高危CHIP个体至关重要。未来,评估预防和/或先发制人治疗策略的前瞻性研究可能有助于避免CHIP个体进展为血癌。